Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
G Mining Delivers Robust Feasibility Study for High-Grade Oko West Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulse Biosciences Inc PLSE

Technology Scientific & Technical Instruments
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other... see more

Recent & Breaking News (NDAQ:PLSE)

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 4 days ago

Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025

Business Wire 5 days ago

Pulse Biosciences' Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting

Business Wire 6 days ago

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results

Business Wire March 27, 2025

Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference

Business Wire March 26, 2025

Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025

Business Wire March 7, 2025

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 4, 2025

Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference

Business Wire February 20, 2025

Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

Business Wire February 4, 2025

Pulse Biosciences' Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting

Business Wire January 30, 2025

Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium

Business Wire January 21, 2025

Pulse Biosciences' Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium

Business Wire January 13, 2025

Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer

Business Wire January 10, 2025

Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire January 3, 2025

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

Business Wire December 23, 2024

Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants

Business Wire December 19, 2024

Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery

Business Wire December 17, 2024

Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association

Business Wire October 31, 2024

Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results

Business Wire October 30, 2024

Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology

Business Wire October 30, 2024